drugset
drugset / Trial / NCT03794297

Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

NCT03794297 ↗

Phase 2 Withdrawn National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies the side effects and how well dabrafenib and trametinib work in treating patients with Erdheim Chester disease that have BRAF V600 gene mutations. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2019-01-04
Primary completion
2021-02-18
Completion
2021-02-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabrafenib Small molecule — Oral
Subject Trametinib Small molecule — Oral

Indications

Erdheim-Chester disease